Showing 6231-6240 of 8473 results for "".
- FDA Follow-Up Study: Sunscreen Active Ingredients Are Absorbed by Bloodstreamhttps://practicaldermatology.com/news/fda-follow-up-study-sunscreen-active-ingredients-are-absorbed-by-bloodstream/2460258/Six active ingredients administered in four different sunscreen formulations are systemically absorbed, according to a new report. The study was sponsored by U.S. Food and Drug Administration (FDA) and is a follow-up to a May 2019 study that generated a lot of headlines. The new report
- Maternal Depression Linked to AD in Kidshttps://practicaldermatology.com/news/maternal-depression-linked-to-ad-in-kids/2460257/Maternal depression in the postpartum period, and even beyond, is associated with the development of atopic dermatitis (AD) throughout childhood and adolescence, according to a recent stu
- Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillershttps://practicaldermatology.com/news/revance-acquires-exclusive-us-distribution-rights-to-teoxane-sa-fillers-1/2460250/Revance Therapeutics, Inc. is the exclusive commercialization partner of Teoxane SA in the US. With a new distribution agreement just announced, Revance gains immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the
- Almirall on the Move with Three New Collabshttps://practicaldermatology.com/news/almirall-on-the-move-with-three-new-collabs/2460248/With three new strategic agreements, Almirall, S.A. is set to strengthen their early-stage research portfolio and expand their pipeline in medical dermatology. Alimirall and 23andMe have signed an agreement allowing Almirall to in-license 23
- New Anti-Acne Launches from Ceravehttps://practicaldermatology.com/news/new-launches-from-cerave/2460236/CeraVe is rolling out
- Castle Creek Completes Acquisition of Fibrocell Sciencehttps://practicaldermatology.com/news/castle-creek-completes-acquisition-of-fibrocell-science/2460235/Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc. Both companies have advanced investigational therapies for the treatment of epidermolysis bullosa (EB) into late-stage clinical research. Prior to the acquisition, Fibrocell initiated a pivot
- Defective Stem Cell Behavior Linked to Psoriasishttps://practicaldermatology.com/news/defective-stem-cell-behavior-linked-to-psoriasis/2460233/Investigators from
- Norfolk Dermatologist Recognized for Increasing Accessibility for Patientshttps://practicaldermatology.com/news/norfolk-dermatologist-recognized-for-increasing-accessibility-for-patients/2460227/Dermatologist Abby Van Voorhees, MD, FAAD, is an American Academy of Dermatology Patient Care Hero for her leadership at the Rapid Access Clinic at the Eastern Virginia Medical School Dermatology Practice in Norfolk, Va. The Eastern Virginia Medical School Dermatology practice allo
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- FDA Accepts NDA for Cassiopea's Clascoterone Cream 1% for Acnehttps://practicaldermatology.com/news/fda-accepts-nda-for-cassiopeas-clascoterone-cream-1-for-acne-1/2460209/The FDA has accepted Cassiopea SpA's New Drug Application (NDA) for clascoterone cream 1% for review. Cassiopea, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological con